India’s Unipath leverages SOPHiA DDM HRD solution to launch HRD Gene panel
Summary
Indian diagnostic service provider Unipath Specialty Laboratory has chosen the SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution of SOPHiA GENETICS, a cloud-native software company in the healthcare industry. Leveraging SOPHiA GENETICS’ technology, Unipath Specialty Laboratory has introduced HRD Gene Panel, its latest offering in the cancer genomics field. It is estimated that the incidence of ovarian cancer is likely to grow by 55% by 2035, with the death rate forecast to rise by 67% to around 254,000 patients. “Through the use of the SOPHiA DDM HRD Solution, Unipath Specialty Laboratory Limited will enhance its genetic testing capabilities, improve disease research and better serve the population in India.” SOPHiA DDM HRD Solution not only enables Unipath Specialty Laboratory to provide thorough genomic insights powered by deep learning algorithms but also has complete ownership of the data, saving time and expense. “We look forward to seeing how this collaboration will advance cancer research and support the work of Unipath Specialty Laboratory Limited in serving the vast community in India.” Besides the SOPHiA DDM HRD Solution, Unipath Specialty Laboratory will leverage SOPHiA GENETICS’ exome analysis services with both full and clinical exome solutions, which will help in identifying indication-based variants in less time and with better accuracy.